We tested this by measuring the serum concentrations of syndecan-4 in patients with DCM of inflammatory and non-inflammatory origin, patients with acute cardiomyopathies, and in patients with acute MI, when admitted and after three and 30 days. This evidence concerns the gene SDC4 and myocardial infarction.